Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,787.00+1.42%ETH$2,289.17+1.82%GOLD$3,931.60-0.96%OIL$96.58+0.12%
Smart Investors Daily
SID Premium
Sumitomo Pharma Co., Ltd. logo

OTC · SMDPY

Sumitomo Pharma Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$12.47

Down-$1.04 (-7.67%)

Updated Nov 3, 2026, 8:25 PM

SID Score

6.0/10

Composite research score

Smart Money

46/100

Neutral

Market cap
4.55B
P/E ratio
5.76
Dividend yield
0.00%
52-week range
— – —
Volume
200
Avg. volume
17

Price performance · SMDPY

SMDPY price history

1M range · 0 trading sessions · Daily adjusted prices

SMDPY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SMDPY news

The latest Smart Investors Daily articles mentioning SMDPY.

Stock researchCompany · Overview

SMDPY research

Overview

Company profile and research snapshot.

Company profile

SUMITOMO PHARMA CO U/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.40
Implied upside
—
Analysts
11
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia

MARLBOROUGH, Mass., October 26, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enzomenib (DSP-5336) for the treatment of patients with relapsed/refractory acute leukemia with KMT2A rearrangement (R/R KMT2Ar). Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leuk

Yahoo · Oct 19, 2026

Sumitomo Pharma (TSE:4506) Could Be 16% Undervalued Following TWYMEEG Sales Growth

Sumitomo Pharma (TSE:4506) has drawn fresh attention after reporting a 29% rise in TWYMEEG® net sales in Japan for the third quarter of 2026 compared with the same period in 2025. The TWYMEEG® update lands while Sumitomo Pharma’s share price has surged in the short term, with a 17.53% 7 day share price return and 43.44% 90 day share price return. However, the year to date share price is still down 23.99%, even as the 3 year total shareholder return is very large, which points to momentum...

Yahoo · Oct 19, 2026

Poxel Reports Revenue for the Third Quarter of 2026

LYON, France, October 19, 2026--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announces its revenue for the third quarter ended September 30, 2026, and for the first nine months of the fiscal year.

Yahoo · Oct 7, 2026

Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight

Recently published Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, emerging schizophrenia drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By